HRMYHarmony Biosciences Holdings, Inc.
Is the price fair?
Neither cheap nor expensive: nothing decisive, though cheap vs its sector.
In its normal range: P/E 13.1 vs a 14.7 median over 22 quarters (−11% vs median).
Sector median 22.6× across 130 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What HRMY's price assumes
Harmony Biosciences Holdings, Inc. trades at 13.1× earnings against 18.8× for the median Biotechnology name, cheaper than its own group.
Trailing P/E · Biotechnology median 18.8 · cheaper than the typical name in its group
- Price / sales
- 2.06
Price / sales · today's price, trailing year to Jun 30, 2026
- Price / book
- 1.98
Price / book · today's price, trailing year to Jun 30, 2026
- EV / sales
- 1.52
EV / sales
Details›
- Price / booktoday's price, trailing year to Jun 30, 2026
- 1.98
- EV / EBITtoday's price, trailing year to Jun 30, 2026
- 6.34
- EV / salestoday's price, trailing year to Jun 30, 2026
- 1.52
- Healthcare median P/E509 names
- 26.2
- Biotechnology median P/E244 names
- 18.8
- Market capitalisation
- $1.98B
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $35.86 |
| Its own P/E history, median | $45.41 |
| Its own P/E history, upper quartile | $58.27 |
| 52-week range | $25.90 – $42.88 |
| Today | $40.31 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.